misonidazole

(redirected from 18F-fluoromisonidazole)

misonidazole

A hypoxic-cell radiosensitising agent administered to patients before administering radiation therapy to increase the cancer kill rate.
Segen's Medical Dictionary. © 2012 Farlex, Inc. All rights reserved.
Mentioned in ?
References in periodicals archive ?
Hybrid imaging (PET/CT) along with radiopharmaceuticals such as 18F-fluorodeoxyglucose (18F-FDG), the most frequently used molecule in the PET diagnosis, 18F-fluorothymidine (18F-FLT), 18F-fluorocholine (18F-FCH), 18F-fluoro-ethyltyrosine (18F-FET), 18F-fluorodihydroxyphenylalanine (18F-FDOPA), 11C-methionine (11C-MET) or 18F-fluoromisonidazole (18F-FMISO), 68Ga-DOTA derivatives, 68Ga-PSMA, 18F-florbetaben or 18F-flutemetamol for brain amyloid beta imaging has been widely used (according to European Journal of Radiology, 2017).
In-depth Research on Radio Pharmaceuticals Market Potential 2018 / Progenics Pharmaceuticals, Inc., NorthStar Medical Radioisotopes LLC, Curium Pharma
Noninvasive assessment of tumor microenvironment using dynamic contrast-enhanced magnetic resonance imaging and 18F-fluoromisonidazole positron emission tomography imaging in neck nodal metastases.
DIAGNOSTIC ACCURACY OF CT SCAN FOR DETECTION OF METASTATIC CERVICAL LYMPH NODES
Model-determined biological aggressiveness assessed by routine magnetic resonance imaging (MRI) was found to be quantitatively linked to the hypoxic burden of the tumor assessed via 18F-fluoromisonidazole positron emission tomography (FMISO-PET) imaging.
Recent peer-reviewed publications by CUR members with undergraduate coauthors
Assessment of hypoxia and perfusion in human brain tumors using PET with 18F-fluoromisonidazole and 15O-H2O.
The role of PET in the management of brain tumors

Medical browser ?
Full browser ?